ITERUM THERAPEUTICS PLC

ITRMF

Current ValuationThe current P/E ratio is 0.00, within the reasonable range, cheaper than 24.82% of the time in the past 1 years, and the industry ranks 60/255, the industry Median -1.32.

-0xP/E
Stock price$0.00

Historical Valuation

P/E ratioTypical rangeMedian

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
0285684112

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x20x40x60x80x100x
P/E ratio
Name/Symbol
TAKUSTakeda Pharmaceutical Company
-56.03x148.12%$58.51B
BAYRYUSBayer
-23.51x--$47.43B
BAYZFUSBayer Aktiengesellschaft
-23.37x--$47.16B
VTRSUSViatris
-48.77x107.75%$20.03B
ELANUSElanco Animal Health
-56.59x129.36%$11.26B
AXSMUSAxsome Therap
-46.49x26.15%$8.91B
VREOFUSVIREO GROWTH INC
-130.38x--$8.75B
CURLFUSCuraleaf Holdings, Inc.
-138.89x--$7.23B
BLTEUSBelite Bio
-60.00x29.87%$6.14B
MANEUSVeraDermics
-50.73x97.44%$5.29B
DFTXUSDefinium Therapeutics
-12.98x53.61%$4.59B
EWTXUSEdgewise Therapeutics
-21.60x137.29%$4.26B
RGCUSRegencell Bioscience
-323.06x--$3.78B
AMLXUSAmylyx Pharmaceuticals
-22.45x1.76%$3.41B
TARSUSTarsus Pharmaceuticals
-68.19x205.82%$3.17B
ELVNUSEnliven Therapeutics
-28.10x6.39%$2.98B
MBXUSMBX Biosciences
-24.59x31.12%$2.56B
SUPNUSSupernus Pharma
-22.29x70.59%$2.45B
BHCUSBausch Health
-2.06x305.55%$2.26B
PHVSUSPharvaris BV
-11.01x10.70%$2.18B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.